Publication | Open Access

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

OncologyMedicinePathologyColorectal CancerDual-targeted TherapyCancer TreatmentPharmacologyRadiation Oncology